![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 3
Zeitschriftenartikel
Harada, Yukinori; Michel, Jonathan; Lohaus, Raphaela; Mayers, Katharina; Emmer, Roberto; Lahmann, Anna Lena; Colleran, Roisin; Giacoppo, Daniele; Wolk, Annabelle; Berg, Jurrien M. ten; Neumann, Franz-Josef; Hans, Yaling; Adriaenssens, Tom; Tölg, Ralph; Seyfarth, Melchior; Maeng, Michael; Zrenner, Bernhard; Jacobshagen, Claudius; Wohrle, Jochen; Kufner, Sebastian; Morath, Tanja; Ibrahim, Tareq; Bernlochner, Isabel; Fischer, Marcus; Schunkert, Heribert; Laugwitz, Karl-Ludwig; Mehilli, Julinda; Byrnes, Robert A.; Kastrati, Adnan und Schulz-Schüpke, Stefanie
(2017):
Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents.
In: Thrombosis and Haemostasis, Bd. 117, Nr. 10: S. 1989-1999
Lohaus, Raphaela; Michel, Jonathan; Mayer, Katharina; Lahmann, Anna Lena; Byrne, Robert A.; Wolk, Annabelle; ten Berg, Jurrien M.; Neumann, Franz-Josef; Han, Yaling; Adriaenssens, Tom; Tölg, Ralph; Seyfarth, Melchior; Maeng, Michael; Zrenner, Bernhard; Jacobshagen, Claudius; Wöhrle, Jochen; Kufner, Sebastian; Morath, Tanja; Ibrahim, Tareq; Bernlochner, Isabell; Fischer, Marcus; Schunkert, Heribert; Laugwitz, Karl-Ludwig; Mehilli, Julinda; Kastrati, Adnan und Schulz-Schüpke, Stefanie
(2016):
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis.
In: Scientific Reports, Bd. 6, 33054
[PDF, 851kB]
Cassese, Salvatore; Kufner, Sebastian; Xhepa, Erion; Byrne, Robert A.; Kreutzer, Johanna; Ibrahim, Tareq; Tiroch, Klaus; Valgimigli, Marco; Tölg, Ralph; Fusaro, Massimiliano; Schunkert, Heribert; Laugwitz, Karl-Ludwig; Mehilli, Julinda und Kastrati, Adnan
(2016):
Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials.
In: Clinical Research in Cardiology, Bd. 105, Nr. 7: S. 575-584